4 Healthcare Stock Stories To Heal the Fitful Trading Day

Johnson & Johnson (NYSE:JNJ): Closing price $84.61

The Johnson & Johnson subsidiary Cordis Corporation has announced the European CE marking and FDA approval of additional sizes of its SLEEK OTW platform, which is a 0.014-inch ultra-low profile percutaneous transluminal angioplasty dilatation catheter. This catheter is a highly deliverable balloon catheter, created to treat patients undergoing peripheral angioplasty procedures below the knee. The device was first introduced on a global basis in 2011, and Cordis will begin commercializing these new sizes immediately in several countries worldwide.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

JNJ

Myriad Genetics (NASDAQ:MYGN): Closing price $26.24

Myriad announced Monday that it has reached an agreement with TESARO through which to conduct BRCA1 and BRCA2 mutation testing on patients to be enrolled in two separate Phase III clinical studies with niraparib. The latter is a novel, orally active poly (ADP-ribose) polymerase, or PARP, inhibitor. TESARO intends to run two Phase III clinical studies with niraparib, while a Phase III evaluation in platinum sensitive, high grade serous ovarian cancer patients is set to begin enrolling in the middle of this year, and a Phase III study in metastatic breast cancer patients having germline BRCA mutations is planned to start in the second half of 2013.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

MYGN

Sanofi-Aventis (NYSE:SNY): Closing price $50.16

Sanofi’s Chief Executive Chris Viehbacher said that a decision by Europe’s drug regulator to release detailed data on drugs after a medicine is okayed could put off critical investments in Europe. Viehbacher took over as president of the European Federation of Pharmaceutical Industries and Associations on Monday and commented that firms would invest in regions where they felt welcome. He told reporters that, ”If you, on the other hand, say, ‘you guys are bad actors, we want to cut your prices, we want to take your confidential data and share it with any one of your competitors’, you don’t get the same feeling of encouragement.” The dispute concerning clinical data transparency worsens a situation in which drugmakers are already holding back on investing in Europe because of a wave of austerity-driven reductions in drug prices.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

SNY

Isis Pharmaceuticals (NASDAQ:ISIS): Closing price $28.42

Isis reported that data from the Phase 2 study of ISIS-APOCIII in patients having high triglycerides and type 2 diabetes were presented Monday at the American Diabetes Association Scientific Sessions in Chicago. In this evaluation, patients treated with ISIS-APOCIII saw an 88 percent reduction in apolipoprotein C-III (apoC-III), marking a 72-percent reduction in triglyceride levels, a 40-percent increase in high-density lipoprotein cholesterol (HDL-C), the ‘good’ cholesterol, and improvements in other atherogenic lipid parameters.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

ISIS

Don’t Miss: Tenet Healthcare Acquires Vanguard in Preparation for Obamacare.